Remission Induction and Sustenance in Graves' Disease 2

Prospective Randomized Study of Therapy Withdrawal vs Continued Low Dose Medical Therapy in Patients With Graves' Disease Entering Remission During ATD Therapy

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00796913

Enrollment

139

Registered

2008-11-24

Start date

2008-01-07

Completion date

2015-05-15

Last updated

2019-01-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Graves Disease, Hyperthyroidism

Brief summary

ATD therapy for Graves' disease is one of the commonly used options for therapy of the hyperthyroidism. The investigators study how to optimally keep patients in remission.

Detailed description

A detailed description of patients entering the initial observational phase of the study (RISG1) has been published: Laurberg P, Nygaard B, Andersen S, Carlé A, Karmisholt J, Krejbjerg A, Pedersen IB, Andersen SL. Association between TSH-Receptor Autoimmunity, Hyperthyroidism, Goitre, and Orbitopathy in 208 Patients Included in the Remission Induction and Sustenance in Graves' Disease Study. J Thyroid Res. 2014;2014:165487. doi: 10.1155/2014/165487.

Interventions

OTHERStop medication

Stop medication Stop medication + se supplement

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

PREVENTION

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Graves hyperthyroidism in remission after ATD

Exclusion criteria

* Age \< 18, severe concomitant disease

Design outcomes

Primary

Measure	Time frame
Relapse of hyperthyroidism	2 years

Secondary

Measure	Time frame
Reoccurrence of TSH-receptor autoimmunity	2 years

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 22, 2026